Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › naloxone

naloxone

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of naloxone

12 trials tracked of naloxone: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 103 citations.

12Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 2 Phase 2 3 Phase 1 4 Other / NA 3
  1. Phase 3 Abuse Liability of Suboxone Versus Subutex Completed · 103 cited
  2. Phase 3 Naloxone for Optimizing Hypoxemia Of Lung Donors Completed · 23 cited
  3. Phase 2 Biology and Experience of Eating in Women With Obesity Completed
  4. Phase 2 Optimal Dose of Prophylactic Naloxone in Reducing Opioid-Induced Side Effects in Children/Adolescents Completed
  5. Phase 2 Treatment of Chronic Itch in Patients Under Arsenic Exposure With Naloxone Completed
  6. Phase 1 Sensory and Opioid Mechanisms of Affective Touch Completed
Show 6 more trials
  1. Phase 1 Chronic Low Back Pain and Meditation Completed
  2. Phase 1 Opioid Antagonism in Hypogonadotropic Hypogonadism Completed
  3. Phase 1 Pharmacodynamic Evaluation of Intranasal Nalmefene Completed
  4. N/A Role of Endorphins in Perception of Dyspnea With Resistive Loading in Chronic Obstructive Pulmonary Disease (COPD) Completed
  5. N/A Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function Completed
  6. N/A Comparison of Two Naloxone Infusion Rates on the Postoperative Recovery of Patients Undergoing Spine Fusion Surgery Completed

Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Intranasal naloxone reverses opioid-induced respiratory depression in opioid-naive and daily users within 2 to 17 minutes
Anesthesiology & Pain Medicine RCT
Intranasal naloxone reverses opioid-induced respiratory depression in opioid-naive and daily users within 2 to 17 minutes Narcan nasal spray reverses opioid breathing depression quickly
This prospective crossover trial enrolled 12 opioid-naive individuals and 18 daily opioid users.
Narcan nasal spray restored breathing within minutes in opioid users, but some had delayed or incomplete recovery.
May 1, 2026
Naloxone prescriptions from US retail pharmacies increased substantially from 2012 to 2018
Infectious Disease
Naloxone prescriptions from US retail pharmacies increased substantially from 2012 to 2018 Did naloxone access improve? Pharmacy prescriptions more than doubled in one year
An observational report of naloxone dispensing trends in US retail pharmacies found the number of prescriptions increased substantially from…
Naloxone prescriptions at U.S. retail pharmacies more than doubled from 2017 to 2018, showing a major jump in access to this life-saving ove…
CDC Apr 6, 2026
Report describes overdose education and naloxone distribution programs in U.S. syringe service programs
Infectious Disease
Report describes overdose education and naloxone distribution programs in U.S. syringe service programs How do syringe programs teach people to stop overdoses?
A report describes overdose education and naloxone distribution (OEND) programs within syringe service programs in the United States.
A new report looks at how syringe service programs across the U.S.
CDC Apr 6, 2026